医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
10期
1944-1945,1948
,共3页
斑蝥/治疗应用%抗肿瘤药(中药)/治疗应用%淋巴瘤/药物疗法
斑蝥/治療應用%抗腫瘤藥(中藥)/治療應用%淋巴瘤/藥物療法
반모/치료응용%항종류약(중약)/치료응용%림파류/약물요법
MYLABRIS/TU%ANTINEOPLASTIC DRUGS (TCD)/TU%Lymphoma/DT
【目的】探讨复方斑蝥胶囊联合CHOP方案化疗对恶性淋巴瘤患者的临床近期疗效。【方法】本院收治的97例恶性淋巴瘤患者,分为对照组( n=51)及观察组( n =46)。对照组单用CHOP方案化疗,观察组在CHOP方案基础上加用复方斑蝥胶囊(一次3粒,每天2次口服)。21 d后重复化疗;疗程结束后进行疗效评定。【结果】观察组总有效率为78.26%(36/46);对照组总有效率为64.70%(33/51);观察组总有效率显著高于对照组,且两组相比较差异有显著性( P <0.05);K PS评分改善率分别是86.96%和66.67%%,且两组相比较差异有显著性( P <0.05);观察组中不良反应低于对照组,且两组相比较差异有显著性( P <0.05)。【结论】复方斑蝥胶囊联合CHOP化疗治疗恶性淋巴瘤的临床近期疗效显著,不良反应低,值得临床推广应用。
【目的】探討複方斑蝥膠囊聯閤CHOP方案化療對噁性淋巴瘤患者的臨床近期療效。【方法】本院收治的97例噁性淋巴瘤患者,分為對照組( n=51)及觀察組( n =46)。對照組單用CHOP方案化療,觀察組在CHOP方案基礎上加用複方斑蝥膠囊(一次3粒,每天2次口服)。21 d後重複化療;療程結束後進行療效評定。【結果】觀察組總有效率為78.26%(36/46);對照組總有效率為64.70%(33/51);觀察組總有效率顯著高于對照組,且兩組相比較差異有顯著性( P <0.05);K PS評分改善率分彆是86.96%和66.67%%,且兩組相比較差異有顯著性( P <0.05);觀察組中不良反應低于對照組,且兩組相比較差異有顯著性( P <0.05)。【結論】複方斑蝥膠囊聯閤CHOP化療治療噁性淋巴瘤的臨床近期療效顯著,不良反應低,值得臨床推廣應用。
【목적】탐토복방반모효낭연합CHOP방안화료대악성림파류환자적림상근기료효。【방법】본원수치적97례악성림파류환자,분위대조조( n=51)급관찰조( n =46)。대조조단용CHOP방안화료,관찰조재CHOP방안기출상가용복방반모효낭(일차3립,매천2차구복)。21 d후중복화료;료정결속후진행료효평정。【결과】관찰조총유효솔위78.26%(36/46);대조조총유효솔위64.70%(33/51);관찰조총유효솔현저고우대조조,차량조상비교차이유현저성( P <0.05);K PS평분개선솔분별시86.96%화66.67%%,차량조상비교차이유현저성( P <0.05);관찰조중불량반응저우대조조,차량조상비교차이유현저성( P <0.05)。【결론】복방반모효낭연합CHOP화료치료악성림파류적림상근기료효현저,불량반응저,치득림상추엄응용。
[Objective]To explore the short‐term efficacy of compound cantharidin capsule combined with CHOP chemotherapy for the treatment of patients with malignant lymphoma .[Methods]Totally 97 patients with malignant lymphoma in our hospital were divided into control group( n=51) and observation group( n=46) .The control group received CHOP regimen ,while the observation group received CHOP regimen combined with oral compound cantharidin capsule(3 capsules once ,twice daily) .Chemotherapy was repeated after 21 days .The effi‐cacy was evaluated after treatment .[Results]The total effective rate in observation group was 78 .26% (36/46) which was markedly higher than that in control group(64 .70% ,33/51) ,and there was significant difference( P<0 .05) .The improvement rate of KPS in observation group and control group was 86 .96% and 66 .67% respective‐ly ,and there was significant difference( P <0 .05) .The incidence of adverse reaction in observation group was lower than that in control group ,and there was significant difference( P<0 .05) .[Conclusion]Compound canthar‐idin capsule combined with chemotherapy for the treatment of malignant lymphoma has significant short‐term effi‐cacy .Therefore ,it is worthy of clinical promotion .